|
|
 |
 |
|
 |
 |
| Empagliflozin now has FDA approval for reducing cardiovascular death or hospitalization among patients with heart failure with preserved left ventricular ejection fraction. ja.ma/3ubpy2u |
|
| 4/12/22, 7:00 AM |
|
|
|
Published by Joseph Thornton MD
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 